LSL Pharma Group Inc.
LSL.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 79.91% | 71.56% | 59.14% | 64.89% | 57.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 79.91% | 71.56% | 59.14% | 64.89% | 57.30% |
| Cost of Revenue | 123.17% | 109.57% | 73.78% | 54.74% | 43.61% |
| Gross Profit | -24.05% | -12.15% | 25.21% | 95.15% | 104.06% |
| SG&A Expenses | 66.23% | 46.66% | 45.32% | 28.50% | 23.49% |
| Depreciation & Amortization | 26.01% | 265.79% | 103.81% | 555.26% | 389.11% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 108.07% | 91.86% | 66.22% | 49.66% | 39.82% |
| Operating Income | -486.96% | -542.28% | -245.14% | 298.70% | 203.68% |
| Income Before Tax | -305.39% | -261.04% | -187.27% | 211.24% | 223.54% |
| Income Tax Expenses | -230.53% | -230.53% | -230.53% | -- | -- |
| Earnings from Continuing Operations | -306.44% | -261.49% | -186.61% | 209.26% | 221.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -306.44% | -261.49% | -186.61% | 209.26% | 221.83% |
| EBIT | -486.96% | -542.28% | -245.14% | 298.70% | 203.68% |
| EBITDA | -155.45% | -126.84% | -22.66% | 832.93% | 14,110.27% |
| EPS Basic | -293.15% | -255.56% | -189.53% | 185.93% | 190.12% |
| Normalized Basic EPS | -510.64% | -300.00% | -100.00% | 63.85% | 69.08% |
| EPS Diluted | -319.50% | -271.28% | -199.42% | 164.68% | 170.18% |
| Normalized Diluted EPS | -510.64% | -300.00% | -100.00% | 63.85% | 69.08% |
| Average Basic Shares Outstanding | 6.66% | 6.48% | 11.65% | 19.78% | 30.08% |
| Average Diluted Shares Outstanding | 6.63% | 6.43% | 11.57% | 19.68% | 30.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |